Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study

出版年份 2020 全文链接

标题

作者

关键词

出版物

Volume -, Issue -, Pages clincanres.0056.2020

出版商

American Association for Cancer Research (AACR)

发表日期

2020-05-13

DOI

10.1158/1078-0432.ccr-20-0056

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now